Hyponatremia Associated with Pulmonary Arterial Hypertension: Syndrome of Inappropriate Antidiuresis Versus Right Heart Failure

Juyeon Kang1, Dae Hyun Lim2, Gheun-Ho Kim3

1Department of Internal Medicine, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan; 2Department of Internal Medicine, National Medical Center, Seoul; 3Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea

Received: November 25, 2020
Revised: December 5, 2020
Accepted: December 5, 2020

Corresponding Author: Gheun-Ho Kim, MD, PhD
Department of Internal Medicine, Hanyang University College of Medicine, 222-1, Wansimni-ro, Seongdong-gu, Seoul 04763, Korea
Tel: +82-2-2290-8318
Fax: +82-2-2298-9183
E-mail: kimgh@hanyang.ac.kr

Because it is associated with mortality, hyponatremia is an important feature of pulmonary arterial hypertension. Its mechanisms remain unclear, although right heart failure resulting from pulmonary arterial hypertension may lead to systemic congestion and arterial underfilling. However, most patients with pulmonary arterial hypertension are clinically euvolemic and have no peripheral edema. Unlike patients with underlying heart disease, neurohumoral activation is not demonstrated in hyponatremic patients with pulmonary arterial hypertension, who show features of congestive heart failure only at later stages in their disease. Here, a case vignette is introduced, and the pathophysiology of hyponatremia in pulmonary arterial hypertension will be discussed. Syndrome of inappropriate antidiuresis (SIAD) appears to underlie hyponatremia in the initial phase of pulmonary arterial hypertension. The mechanisms by which various lung diseases can lead to SIAD remain an enigma.

Key Words: Hyponatremia, Pulmonary arterial hypertension, Right heart failure, Syndrome of inappropriate antidiuresis

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Case Vignette

A 70-year-old female was admitted for evaluation of hyponatremia. She was previously well until a skin rash appeared five years prior to admission. Two years thereafter, she visited a hospital because of exertional dyspnea and recurrent skin rash and was diagnosed with pulmonary arterial hypertension (PAH) and systemic lupus erythematosus (SLE) by cardiac catheterization (mean pulmonary arterial pressure, 50 mmHg) and serologic tests, respectively. Echocardiography revealed an enlarged right atrium and ventricle, moderate tricuspid regurgitation, and an estimated systolic pulmonary arterial pressure of 71 mmHg. However, left ventricular systolic function was normal.

At presentation, she complained of general weakness and nausea. Hypocomplementemia (C3, 26 mg/dL; C4, 2 mg/dL) was noted, but erythrocyte sedimentation rate was normal (18 mm/h). Her serum sodium was 125 mmol/L, and she was euvolemic on physical examination. Serum osmolality was 260 mOsm/kg H2O, urine osmolality 326 mOsm/kg H2O, urine sodium 66 mmol/L, blood urea nitrogen 8.6 mg/dL, serum creatinine 0.72 mg/dL, and serum uric acid 3.1 mg/dL. Hypothyroidism and adrenal insufficiency were excluded. The level of brain natriuretic peptide (BNP) was 27 pg/mL. Arterial blood gas analysis showed pH 7.43, PaCO2 29.7 mmHg, PaO2 97.6 mm Hg, and HCO3- 19.1 mmol/L.

Pathogenesis and Differential Diagnosis of Hyponatremia

Hyponatremia occurs when water is primarily or secon-
darily retained in the body. The primary causes of water retention are pure water balance disorders such as primary polydipsia and syndrome of inappropriate antidiuresis (SIAD). On the other hand, the secondary causes of water retention accompany sodium balance disorders. When sodium is depleted (e.g., vomiting), neurohumoral activation stimulates vasopressin release and induces renal water retention. When extracellular fluid sodium is excessive (e.g., congestive heart failure), decreased effective arterial blood volume also enhances vasopressin release and leads to dilutional hyponatremia. Thus, a patient’s volume status, whether hypovolemic or hypervolemic, is an important clue in the differential diagnosis of hyponatremia. When the patient appears euvolemic, the differential diagnosis is more challenging.

SIAD is the prototype of euvolemic hyponatremia and includes the syndrome of inappropriate secretion of antidiuretic hormone (SIADH), reset osmostat, and nephrogenic syndrome of inappropriate antidiuresis (NSIAD). Whereas reset osmostat has a subnormal threshold for antidiuretic hormone secretion, NSIAD is characterized by suppressed levels of plasma vasopressin irrespective of plasma sodium concentrations. In clinical practice, however, it is very difficult to differentiate between SIADH and NSIAD because correct routine measurement of plasma vasopressin is not feasible. Thus, “SIAD” is frequently diagnosed based on its diagnostic criteria1).

Causes of Syndrome of Inappropriate Antidiuresis (SIAD)

From the viewpoint of channelopathy, NSIAD is the mirror image of nephrogenic diabetes insipidus (NDI). Loss-of-function vasopressin-2 receptor mutations cause NDI, whereas gain-of-function mutations cause NSIAD2). Activity of the vasopressin-2 receptor is connected to trafficking of aquaporin-2 water channel to the apical membrane and increasing the abundance of aquaporin-2 mRNA and protein. Thus, the activity of either vasopressin-2 receptor or aquaporin is enhanced in NSIAD.

The causes of SIAD are largely divided into enhanced vasopressin release and potentiation of the renal action of vasopressin3). The latter may be interpreted as spontaneous aquaporin-2 hyperactivity. However, the detailed etiology remains unclear. Vasopressin hypersecretion was demonstrated in only a few cases of neoplasm, lung or central nervous system disorders, and drug-induced hyponatremia. Notably, drugs are an important cause of NSIAD by upregulating the vasopressin-2 receptor mRNA3).

PAH, SLE, and Hyponatremia

PAH is caused by diffuse pulmonary artery vasculopathy, leading to progressive narrowing of the vessel lumen4). PAH belongs to World Health Organization (WHO) group 1 pulmonary hypertension (PH), which includes idiopathic PAH, heritable PAH, connective tissue disease-associated PAH (CTD-PAH), congenital heart disease-associated PAH (CHD-PAH), portopulmonary hypertension (PoPH), and PH associated with HIV, schistosomiasis, anorexic drugs, and toxins5).

Systemic sclerosis is the leading cause of CTD-PAH, followed by SLE, mixed connective tissue disease, idiopathic inflammatory myositis, rheumatoid arthritis, and Sjogren’s syndrome6). However, PAH is a rare complication of SLE. Prabu et al. reported that the point prevalence of PAH was 4.2% in their British cohort of patients with SLE, and most of their PAH cases were found to be of mild severity (systolic pulmonary artery pressure <40 mmHg)7).

Hyponatremia may be a poor prognostic marker in PAH. Rudkovskaia et al. reported that 31 patients had severe hyponatremia (<130 mmol/L) in two different cohorts (n=1,611 total) and that severe hyponatremia was associated with higher overall mortality8). According to Forfia et al., hyponatremia was strongly associated with right heart failure and poor survival in PAH9). However, right heart failure is only an advanced feature of PAH.

Right Heart Failure Versus SIAD

The mechanism of hyponatremia in PAH has not been established. Patients with PAH are typically euvolemic and may be edematous at late stages. In patients with cor pulmonale (group 3 PH), the renin-angiotensin-aldosterone axis is stimulated in response to right ventricular failure10). This effect may relate to arterial underfilling associated with a decrease in systemic vascular resistance11).
However, neurohumoral activation appears different between right and left ventricular failure. Arterial underfilling, as a result of either a decrease in cardiac output or systemic arterial vasodilation, may not be present with PAH\[^{11}\]. The neurohumoral axis has rarely been studied in PAH with right ventricular failure in humans. Nootens et al. reported that patients with PAH showed increases in plasma endothelin, atrial natriuretic peptide, and norepinephrine concentrations but not in plasma renin activity. Plasma aldosterone and vasopressin levels were not assessed\[^{12}\].

Thus, we postulate that a different mechanism induces hyponatremia during the early phase of PAH (group 1 PH) because the BNP level was normal in our case. Additionally, our case showed the following findings compatible with SIAD: (1) decreased serum osmolality, (2) urine osmolality >100 mOsm/kg H\(_2\)O, (3) clinical euvolemma, (4) urine sodium >40 mmol/L, (5) serum uric acid <4 mg/dL, and (6) absence of renal failure, hypothyroidism, and adrenal insufficiency. Because pulmonary artery vasculopathy is a lung disease, it might cause SIAD via inducing vasopressin hypersecretion or aquaporin-2 hyperactivity.

**Can PAH Cause SIAD?**

Pulmonary infection and malignancy are the major causes of SIAD among various lung disorders. However, other pulmonary disorders can induce SIAD, including asthma, cystic fibrosis, and respiratory failure associated with positive pressure breathing\[^{1}\]. We found no case reports of SIAD or SIADH in patients with PAH. Right heart failure has been regarded as a cause of renal sodium and water retention. However, whether the early stages of PAH and right heart failure are associated with neurohumoral activation remains unclear\[^{11}\]. Considering the possibility of SIAD in PAH, the use of vasopressin-2 receptor antagonists would be warranted.

On the other hand, previous studies reported that disease activity was associated with hyponatremia in SLE\[^{13,14}\]. Active SLE frequently involves the kidneys, lungs, and central nervous system. Stressful conditions may also stimulate vasopressin release. Although the excessive unsuppressible release of vasopressin was not clearly demonstrated, SIADH was reported in the patients with SLE\[^{15,16}\]. The mechanism by which SIAD is induced in pulmonary disorders other than ectopic vasopressin production is poorly understood. Hypoxia, hypercapnia, and decreased vascular volume have been attributed\[^{1,17,18}\], but these factors were not compatible with our case. Can NSIAD be induced by pulmonary disorders? The lung may be an important endocrine organ in disease\[^{19}\], and a certain signaling cascade may reach the kidney and act as a ligand to the vasopressin-2 receptor, thereby stimulating aquaporin-2 trafficking and production\[^{20}\]. Further studies are required to elucidate the mechanisms by which various pulmonary disorders cause SIAD.

**Acknowledgments**

This work was supported by the National Research Foundation (NRF) of Korea funded by the Korean government (2018R1D1A1A02047590).

**Conflict of interest**

The authors have no conflicts of interest to declare.

**ORCID:** Gheun-Ho Kim 0000-0002-8445-9892

**REFERENCES**

1. Ellison DH, Berl T: Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 356:2064-2072, 2007
2. Knoers NV: Hyperactive vasopressin receptors and disturbed water homeostasis. N Engl J Med 352:1847-1850, 2005
3. Kim S, Choi HJ, Jo CH, et al.: Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney. Am J Physiol Renal Physiol 309:F474-F483, 2015
4. Tuder RM, Archer SL, Dorfmuller P, et al.: Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D4-D12, 2013
5. Simonneau G, Gatzoulis MA, Adatia I, et al.: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62(25 Suppl):D34-D41, 2013
6. Thakkar V, Lau EM: Connective tissue disease-related pulmonary arterial hypertension. Best Pract Res Clin Rheumatol 30:22-38, 2016
7. Prabu A, Patel K, Yee CS, et al.: Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus.
8. Rudkovskaia AA, Tonelli AR, Rao Y, et al.: Is hyponatremia associated with mortality in pulmonary arterial hypertension? Pulm Circ 8:2045894018776888, 2018
9. Forfia PR, Mathai SC, Fisher MR, al.: Hyponatremia predicts right heart failure and poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 177:1364-1369, 2008
10. Anand IS, Chandrashekhar Y, Ferrari R, et al.: Pathogenesis of congestive state in chronic obstructive pulmonary disease: Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 86:12-21, 1992
11. Schrier RW, Bansal S: Pulmonary hypertension, right ventricular failure, and kidney: Different from left ventricular failure? Clin J Am Soc Nephrol 3:1232-1237, 2008
12. Nootens M, Kaufmann E, Rector T, et al.: Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 26:1581-1585, 1995
13. Il Shin J, Park SJ, Suh CH, et al.: Hyponatremia in patients with systemic lupus erythematosus. Sci Rep 6:25566, 2016
14. Yamany A, Behiry ME, Ahmed SA: Hyponatremia as an inflammatory marker of lupus activity is a fact or fad: A cross-sectional study. Open Access Rheumatol 12:29-34, 2020
15. Martín Santos JM, Terroba Larumbe MC, Dib B, Armentia Medina A: Systemic lupus erythematosus and the syndrome of inappropriate secretion of antidiuretic hormone. Clin Exp Rheumatol 14:578-579, 1996
16. Elisaf MS, Milionis HJ, Drosos AA: Hyponatremia due to inappropriate secretion of antidiuretic hormone in a patient with systemic lupus erythematosus. Clin Exp Rheumatol 17:223-226, 1999
17. Lee P, Ho KK: Hyponatremia in pulmonary TB: Evidence of ectopic antidiuretic hormone production. Chest 137:207-208, 2010
18. Valli G, Fedeli A, Antonucci R, Paoletti P, Palange P: Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis 61:112-116, 2004
19. Fuentes N, Silveyra P: Endocrine regulation of lung disease and inflammation. Exp Biol Med (Maywood) 243:1313-1322, 2018
20. Jung HJ, Kwon TH: New insights into the transcriptional regulation of aquaporin-2 and the treatment of X-linked nephrogenic diabetes insipidus. Kidney Res Clin Pract 38:145-158, 2019